real-time news and commentary for investors
Friday, Dec 21
2012, 10:16 AM
Sarepta (SRPT -0.5%) says it's entered into a Clinical Trial Agreement with the National...
Sarepta (SRPT -0.5%) says it's entered into a Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases to conduct a Phase I study with its experimental flu vaccine and lead drug candidate, AVI-7100. The drug has the potential to address a broad-spectrum of influenza viruses, including Tamiflu-resistant virus strains. Separately, The Street's Adam Feuerstein called the stock a top biotech pick for 2013, saying its Duchenne muscular dystrophy treatment, eteplirsen, and is poised for accelerated approval.